Saturday, November 11, 2017 4:14:14 PM
My understanding (welcome correction, if wrong–please tell) is that cells retain functioning sigma-1 receptors at all ages. The reason so many central nervous system diseases strike with age (such as Alzheimer’s, Parkinson’s) is that with time, certain organelles that are normally connected and function collaboratively get broken apart.
That’s where and why Anavex 2-73 works so well as effective treatments for diseases such as Alzheimer’s and Parkinson’s. Both (and many other CNS diseases) are known to involve mitochondrial dysfunction. Mitochondria are complex organelles that, among other things, house the electron transport system, a complex arrangement of structures and chemical reactions that delicately extract energy from glucose (or some other energy feedstocks), transferring it to adenosine triphosphate (ATP). ATP is then shuffled off to other cell structures where the contained bond energy is released to power virtually all cellular processes. A car runs on gasoline. Cells (for the most part) run on ATP.
But in the case of geriatric CNS diseases, the ATP the mitochondria synthesize does not effectively or efficiently get transported off to the adjacent endoplasmic reticula, organelles that are normally in contact with mitochondria. With this contact, they receive ample ATP supplies, which power the essential functions of the endoplasmic reticula.
And one of those functions is to properly fold synthesized proteins into effective enzymes. If folded properly (which requires sufficient ATP), the folded proteins, enzymes, control and facilitate all of the normal chemical reactions of the cell. With properly folded enzymes, the cell works as it should. (Many toxins are lethal because they get into cells and disrupt normal protein folding. A mis-folded enzyme is exactly like a bent car key. It can’t open the door or start the engine.)
Again, Anavex 2-73 has the unique ability to re-connect dissembled endoplasmic reticula and mitochondria, so ATP exchange works; proteins (enzymes) are properly synthesized. Anavex 2-73 works because of the sigma-1 receptors, molecular binding sites on the two organelles. If they are retained into older age—as I believe they are—Anavex 2-73 is able to cause the two organelles to resume their adjacent connected state.
So (to answer the question), increase in CNS disease is not a loss of sigma-1 receptors with age; rather, it’s the “wearing out” of the cells themselves, where the two organelles break apart with age and no longer work collaboratively (factors other than age can cause this, too).
In effect, Anavex 2-73 is a cellular rejuvenation molecule, restoring the cell to a more functional, un-aged condition. It puts important things back together, so they can work normally.
(Yes, there is much more to all of this, but these are the core, essential phenomena.)
Recent AVXL News
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM